NMI 900 companion diagnostic - Medical Prognosis Institute

Drug Profile

NMI 900 companion diagnostic - Medical Prognosis Institute

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medical Prognosis Institute
  • Developer Medical Prognosis Institute; Nemucore Medical Innovations
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 20 Jan 2016 Phase-II clinical trials in Ovarian cancer (Diagnosis) in USA (unspecified route) before January 2016
  • 07 Dec 2015 Early research in Solid tumours (Diagnosis) in USA (unspecified route)
  • 07 Dec 2015 Nemucore plans a phase IIb trial for advanced ovarian cancer in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top